3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
3
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Glioma
2
Glioblastoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
Bevacizumab
6
Everolimus
4
Sirolimus
2
Lapatinib
2
HDAC-42
2
vistusertib
1
temsirolimus
1
neratinib
1
icotinib
1
emvododstat
1
brolucizumab
1
brigatinib
1
aflibercept
1
Vascular Endothelial Growth Factor A
1
Valproic Acid
1
Sunitinib
1
Magnetic Resonance Imaging
1
Immunoglobulin G
1
Exome
1
Endostatins
1
Doxycycline
1
Disulfides
1
Crizotinib
1
Cetuximab
1
Axitinib
1
Aspirin
1
AZD 6244
1
89Zr-bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibromatosis 2
×
Crizotinib
×
CNS
×
Clear all
NCT04283669
2026-03-13
NF110
University of Alabama at Birmingham
Phase 2
Completed
12 enrolled
5 charts